Abstract
There has been a rapid aging of the population worldwide, with the subgroup aged 80?85 years increasing most rapidly in number. Cardiovascular disease is the most prevalent and lethal health problem in the elderly.
Under-representation of the elderly patients in the clinical trials tends to result in undertreatment with the newer intervention modalities that have been shown to be highly effective in younger age groups. In the present we have some data about effectivity of specific therapeutic modalities in the elderly people, for example registries of patients who were treated by percutaneous reperfusion therapy showed effectivity and safety of this method